TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03714997

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Walking training
Description: Practice of walking training in variable contexts, including multiple tasks and environments specific to the patients' deficits and community walking goals.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Walking training
Description: Practice of walking training in variable contexts, including multiple tasks and environments specific to the patients' deficits and community walking goals.
Study: NCT03838731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1908-1909
Description: Single subcutaneous (SC) dose of REGN1908 and REGN1909

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single subcutaneous (SC) dose of matching placebo
Study: NCT03752177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3415244
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3415244
Description: Administered IV
Study: NCT06062004

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small Incision Lenticule Extraction (SMILE)
Description: All surgeries will be performed under topical anesthesia using the VisuMax femtosecond laser with the following parameters:~* Cap thickness of 120 μm~* Cap diameter of 1 mm larger than the lenticule diameter~* Cap side cut angle 70°~* 3 mm incision positioned at 100° and angled at 45°~* Transition zone of 0.1 mm and clearance of 0.5 mm~* Lenticule side cut angle of 90° and edge lenticule thickness of 15 μm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small Incision Lenticule Extraction (SMILE)
Description: All surgeries will be performed under topical anesthesia using the VisuMax femtosecond laser with the following parameters:~* Cap thickness of 120 μm~* Cap diameter of 1 mm larger than the lenticule diameter~* Cap side cut angle 70°~* 3 mm incision positioned at 100° and angled at 45°~* Transition zone of 0.1 mm and clearance of 0.5 mm~* Lenticule side cut angle of 90° and edge lenticule thickness of 15 μm
Study: NCT00770809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib Ditosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib Ditosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Given IV
Study: NCT01478451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise will be performed for 10 minutes at the left or right trapezius (randomized)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: massage will be provided for 10 minutes at the left or right trapezius (randomized)
Study: NCT00006244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: Given SC
Study: NCT04465266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolperisone
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolperisone
Description: tablets
Study: NCT00006244

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro-treated peripheral blood stem cell transplantation
Description: Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
Study: NCT03216369

Intervention type: OTHER
Intervention: MRI
Description: MRI perfusion imaging
Study: NCT01220726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: Botox injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection
Study: NCT02579382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: 300 mg tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: 300 mg tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: 300 mg tablets administered orally once daily
Study: NCT04465266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolperisone
Description: tablets
Study: NCT02931422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Conditional cash transfer upon HIV testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Conditional cash transfer upon HIV testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Conditional cash transfer upon HIV testing
Study: NCT03745677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advanced and Integrated MicroSystems (AIMS) interventions
Description: Each of 4 sites is receiving mentorship from nurse and physician with expertise in implementing similar interventions. The AIMS interventions consist of 1) unit-based physician teams, 2) unit nurse-physician co-leadership, 3) enhanced interprofessional rounds, 4) unit-level performance reports, and 5) patient engagement activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advanced and Integrated MicroSystems (AIMS) interventions
Description: Each of 4 sites is receiving mentorship from nurse and physician with expertise in implementing similar interventions. The AIMS interventions consist of 1) unit-based physician teams, 2) unit nurse-physician co-leadership, 3) enhanced interprofessional rounds, 4) unit-level performance reports, and 5) patient engagement activities.
Study: NCT02579382

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TDF
Description: 300 mg tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Tablets administered orally once a week (every 7 days) for 12 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Tablets administered orally once a week (every 7 days) for 12 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Tablets administered orally once a week (every 7 days) for 12 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally once a week (every 7 days) for 12 doses
Study: NCT03815435

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Controlled hypotension
Description: Controlled hypotension will be administered according to the clarity of the surgical field.
Study: NCT01212159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self Monitoring Lipid Analyzer
Description: The device is similar to a glucometer- Utilizing a lancet a small amount of blood is collected in a capillary tube and placed on a hand held monitor that records lipid values.
Study: NCT03818009

Intervention type: OTHER
Intervention: Assessment document
Description: The anesthesiologist will evaluate through his sheet women's cognitive functions.

Intervention type: OTHER
Intervention: Assessment document
Description: The anesthesiologist will evaluate through his sheet women's cognitive functions.
Study: NCT04676152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo Noninvasive Blood Pressure Device
Description: Non-invasive blood pressure device
Study: NCT01532258

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Go! Foods for You without Weekly MA Support.
Description: * Participants access and utilize an 8-week online program which provides educational materials and weekly activities based on a Mediterranean diet and dietary practices that have been associated with healthy weights.~* Each day participants receive educational materials related to the nutritional science of a Mediterranean diet. Each week (1) a new theme for the daily educational materials is presented and (2) participants are asked to schedule activities on a built in calendar and practice the activity throughout the week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Go! Foods for You with Weekly MA Support.
Description: * Participants access and utilize an 8-week online program which provides educational materials and weekly activities based on a Mediterranean diet and dietary practices that have been associated with healthy weights.~* In addition to the 8-week online program, participants receive weekly support by Medical Assistants (MA) over the phone or by email to establish a relationship and maintain program adherence by discussing the previous week's behavioral goals and setting weekly behavioral goals.
Study: NCT01299896

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coordinated Care
Description: CTQ coordinators will contact the participants for various information sessions about the participant's smoking. These participants will also receive our Connecting to Quit newsletter quarterly.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard therapy to help participants with smoking cessation.
Study: NCT02706145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social norming campaign
Description: community-level, three-year social norming campaign, using traditional and emerging media, aimed at changing norms of violence among youth 10-24
Study: NCT03139409

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adhesive bond with chlorhexidine
Description: Peak® Universal Bond (ultradent, 505 West 10200 South, South Jordan, UT 84095،USA ) light-Cured Adhesive with Chlorhexidine (0.2%), 7.5% filler, phosphate and containing hydroxyethyl methacrylate with ethyl alcohol as the carrier. its viscosity has been optimized for minimal film thickness (2μm) and superior strength. using self etch adhesive with chlorexidine as one step in the bonding component may give chance to proper penetration of resin tags, decrease the micro-organisms due to the antibacterial effect of chlorexidine (Bin-Shuwaish, 2016) and also the addition of chlorexidine in bonding system may be an excellent tool to increase the stability of collagen fibrils within the hybrid layer against host-derived metaloproteinases (MMP) without the need for additional steps for the bonding protocol (Stanislawczuk, et al., 2009), which results in better durability and good restorations with decreasing the incidence of recurrent caries

Intervention type: OTHER
Group type: OTHER
Intervention: Time variable
Description: Diagnosis and follow up will be immediate , 6 months later and 1 year
Study: NCT03181945

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 4 weeks
Description: Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 4 weeks followed by taper in 10-14days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 12 weeks
Description: Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 12 weeks followed by taper in 10-14days
Study: NCT02688803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dose dense AC-P
Description: (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 175 mg/m2 q2weeks x 4 cycles)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dose dense AC
Description: Dose dense AC followed by weekly P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 80 mg/m2 weekly x 12 cycles)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FEC-D
Description: FEC-D (5-FU 500 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 q3weeks x 3 cycles followed by docetaxel 100 mg/m2 q3weeks x 3 cycles)
Study: NCT04162405

Intervention type: BEHAVIORAL
Intervention: Tinnitus Handicap Inventory Test
Description: A prospective cohort nonrandomized study of non-masked parallel paired groups. The data will be collected from an electronic database that is filled in during diagnostic processing. During the diagnostic processing, TSI and THI questionnaires will be filled in, a tone audiogram (TA) and DPOAE will be performed.

Intervention type: BEHAVIORAL
Intervention: Tinnitus Handicap Inventory Test
Description: A prospective cohort nonrandomized study of non-masked parallel paired groups. The data will be collected from an electronic database that is filled in during diagnostic processing. During the diagnostic processing, TSI and THI questionnaires will be filled in, a tone audiogram (TA) and DPOAE will be performed.
Study: NCT02748759

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPM
Description: 15 repetitions of flexo-extensión with a commercially available CPM device (Kinetec Advanced Prima)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPM
Description: 15 repetitions of flexo-extensión with a commercially available CPM device (Kinetec Advanced Prima)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual mobilization
Description: Manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual mobilization
Description: Manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist
Study: NCT02501941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: Ketamine will be used as a sedative alternative to other more conventional sedatives (such as propofol, versed, or dexmedetomidine) in 6 hour blocks of time. Ketamine will be titrated at the bedside based on clinically desired Riker Sedation-Agitation Scale target. Both groups will receive the drug in this multiple crossover design. The only difference between groups is which sedation regimen is started first to minimize any bias related to differences in physiology in the early post-operative phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: Ketamine will be used as a sedative alternative to other more conventional sedatives (such as propofol, versed, or dexmedetomidine) in 6 hour blocks of time. Ketamine will be titrated at the bedside based on clinically desired Riker Sedation-Agitation Scale target. Both groups will receive the drug in this multiple crossover design. The only difference between groups is which sedation regimen is started first to minimize any bias related to differences in physiology in the early post-operative phase.
Study: NCT00639106

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alloderm, Questionnaires
Description: All patients will undergo placement of a temporary tissue expander immediately following mastectomy.Patients will undergo the surgical creation of an expander pocket using implantable Alloderm.
Study: NCT03525262

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 30Gy (Gray) planning target volume (PTV)
Description: PTV1_30Gy represents a 3mm expansion on the prostate (and proximal seminal vesicle per physician discretion), excluding the neurovascular structures on the side to be spared (left or right). PTV1 will receive 6 Gy per fraction for 5 fractions (30 Gy).
Study: NCT02834767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genioglossis Strength Trainer
Description: The genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. The device can be set to a specific pressure resistance ranging from 10 to 40 Newtons. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genioglossis Strength Trainer
Description: The genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. The device can be set to a specific pressure resistance ranging from 10 to 40 Newtons. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Genioglossis Strength Trainer
Description: The placebo genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. Whereas the pressure loaded spring in the active trainer can be set to a wide range of pressures, the placebo trainer has a maximum resistance of 5 Newtons. The device is set to a specific pressure resistance of 5 Newtons at all times. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Genioglossis Strength Trainer
Description: The placebo genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. Whereas the pressure loaded spring in the active trainer can be set to a wide range of pressures, the placebo trainer has a maximum resistance of 5 Newtons. The device is set to a specific pressure resistance of 5 Newtons at all times. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).
Study: NCT02412735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rexlemestrocel-L
Description: Rexlemestrocel-L injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rexlemestrocel-L + HA Mixture
Description: Rexlemestrocel-L was combined in 1:1 by-volume ratio with HA solution and the resulting mixture was injected

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline control solution
Study: NCT01508949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
Study: NCT04329637

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrative healt care
Description: Meditation and use of a care cordinator
Study: NCT04219995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone sodium succinate
Description: Methylprednisolone sodium succinate will be re-constituted in simple syrup in a concentration of 80mg/mL and will be administered orally at 20mg/kg (max 1000mg) for days 1, 2, and 3 of the intervention phase of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone sodium succinate
Description: Methylprednisolone sodium succinate will be re-constituted in simple syrup in a concentration of 80mg/mL and will be administered orally at 20mg/kg (max 1000mg) for days 1, 2, and 3 of the intervention phase of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo used in this study will be simple syrup.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo used in this study will be simple syrup.
Study: NCT01008553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
Study: NCT00400998

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone Propionate
Description: Subjects will receive the following treatment regimen over one of two dosing periods within each of the three study phases:~- Intranasal FPANS (Fluticasone Propionate aqueous nasal spray) 200 mcg once daily for 8 to 14 days i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL (microlitres) i.e. 50 mcg fluticasone propionate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone Propionate
Description: Subjects will receive the following treatment regimen over one of two dosing periods within each of the three study phases:~- Intranasal FPANS (Fluticasone Propionate aqueous nasal spray) 200 mcg once daily for 8 to 14 days i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL (microlitres) i.e. 50 mcg fluticasone propionate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone Propionate
Description: Subjects will receive the following treatment regimen over one of two dosing periods within each of the three study phases:~- Intranasal FPANS (Fluticasone Propionate aqueous nasal spray) 200 mcg once daily for 8 to 14 days i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL (microlitres) i.e. 50 mcg fluticasone propionate.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched FPANS placebo
Description: Subjects will receive the following placebo treatment regimen over one of two dosing periods within each of the three study phases:~* Intranasal FPANS placebo once daily for 8 to 14 days (i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched FPANS placebo
Description: Subjects will receive the following placebo treatment regimen over one of two dosing periods within each of the three study phases:~* Intranasal FPANS placebo once daily for 8 to 14 days (i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched FPANS placebo
Description: Subjects will receive the following placebo treatment regimen over one of two dosing periods within each of the three study phases:~* Intranasal FPANS placebo once daily for 8 to 14 days (i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL.